Akebia Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2007-01-01

Employees: 167

Market Cap: $319.6M

Website: http://www.akebia.com

Introduction: Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Clinical Trials

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)

Phase 2

Completed

Conditions: Anemia
Non-dialysis Dependent Chronic Kidney Disease

Interventions: Drug: Placebo
Drug: Vadadustat

First Posted Date: 2017-02-15

Last Posted Date: 2021-04-08

Lead Sponsor: Akebia Therapeutics

Target Recruit Count: 51

Registration Number: NCT03054337

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Phase 2

Completed

Conditions: Anemia
Dialysis Dependent Chronic Kidney Disease

Interventions: Drug: Vadadustat
Drug: Placebo

First Posted Date: 2017-02-15

Last Posted Date: 2021-04-08

Lead Sponsor: Akebia Therapeutics

Target Recruit Count: 60

Registration Number: NCT03054350

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Phase 3

Completed

Conditions: Dialysis-Dependent Chronic Kidney Disease
Anemia

Interventions: Drug: Vadadustat
Drug: Darbepoetin alfa

First Posted Date: 2016-09-08

Last Posted Date: 2022-06-28

Lead Sponsor: Akebia Therapeutics

Target Recruit Count: 3554

Registration Number: NCT02892149

Locations: 🇺🇸
AMPM Research Clinic, Miami, Florida, United States
🇬🇧
Research Site, Doncaster, South Yorkshire, United Kingdom
🇺🇦
Research Site #1, Cherkassy, Ukraine

and more 3 locations

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Phase 3

Completed

Conditions: Dialysis-Dependent Chronic Kidney Disease
Anemia

Interventions: Drug: Vadadustat
Drug: Darbepoetin alfa

First Posted Date: 2016-08-15

Last Posted Date: 2022-07-18

Lead Sponsor: Akebia Therapeutics

Target Recruit Count: 369

Registration Number: NCT02865850

Locations: 🇺🇦
Research Site, Zhytomyr, Ukraine
🇺🇸
Research Site #1, Chattanooga, Tennessee, United States
🇷🇺
Research Site #2, Kemerovo, Russian Federation

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Phase 3

Completed

Conditions: Non-Dialysis-Dependent Chronic Kidney Disease
Anemia

Interventions: Drug: Vadadustat
Drug: Darbepoetin alfa

First Posted Date: 2016-02-11

Last Posted Date: 2022-06-27

Lead Sponsor: Akebia Therapeutics

Target Recruit Count: 1725

Registration Number: NCT02680574

Locations: 🇷🇸
Research Site #3, Belgrade, Serbia
🇿🇦
Research Site #1, Durban, KwaZulu-Natal, South Africa
🇿🇦
Research Site #2, Durban, KwaZulu-Natal, South Africa

and more 1 locations

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Phase 3

Completed

Conditions: Anemia
Non-Dialysis-Dependent Chronic Kidney Disease

Interventions: Drug: Vadadustat
Drug: Darbepoetin alfa

First Posted Date: 2016-01-07

Last Posted Date: 2022-06-27

Lead Sponsor: Akebia Therapeutics

Target Recruit Count: 1751

Registration Number: NCT02648347

Locations: 🇬🇧
Research Site, Swansea, United Kingdom
🇿🇦
Research Site #1, Durban, KwaZulu-Natal, South Africa
🇿🇦
Research Site #2, Durban, KwaZulu-Natal, South Africa

and more 1 locations

Effect of AKB-6548 on the Pharmacokinetics of Celecoxib

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Celecoxib
Drug: AKB-6548

First Posted Date: 2015-07-20

Last Posted Date: 2018-11-14

Lead Sponsor: Akebia Therapeutics

Target Recruit Count: 12

Registration Number: NCT02502500

Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: AKB-6548 tablet, reference formulation given in the fasted state
Drug: AKB-6548 tablet, test formulation given in the fasted state.
Drug: AKB-6548 tablet, test formulation given in the fed state